Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

NasdaqGM:IRON
NasdaqGM:IRONBiotechs

A Look At Disc Medicine (IRON) Valuation After Recent Share Price Swings

Disc Medicine stock reacts after recent share price moves Disc Medicine (IRON) has drawn attention after recent share price swings, including a 5.0% gain over the past day, offset by declines over the past week, month, and past 3 months. See our latest analysis for Disc Medicine. The latest 1 day share price gain sits against weaker short term momentum, with the 30 day share price return of 19.43% decline and 90 day share price return of 29.97% decline contrasting with a 1 year total...
NasdaqGS:ERII
NasdaqGS:ERIIMachinery

A Look At Energy Recovery (ERII) Valuation After PX Q650 Desalination Launch

Why the PX Q650 launch matters for Energy Recovery (ERII) investors Energy Recovery (ERII) has drawn fresh attention after launching its PX Q650 Pressure Exchanger for desalination, combining higher flow capacity, very high stated efficiency, and extended warranties aimed at long-life plant operations. See our latest analysis for Energy Recovery. The PX Q650 launch comes on the heels of Energy Recovery’s recent earnings update. It arrives at a time when the stock has seen a 4.81% 1 day share...
NYSE:DT
NYSE:DTSoftware

Dynatrace (DT) Is Up 5.9% After EVP Share Purchase And AI Platform Spotlight – Has The Bull Case Changed?

In late February and early March 2026, Dynatrace drew attention as Executive Vice President Stephen McMahon bought 3,000 company shares for about US$107,250 and the firm highlighted its artificial intelligence-driven observability platform at Morgan Stanley’s Technology, Media & Telecom Conference in San Francisco. This combination of insider buying and a public focus on AI-enabled growth and raised profit guidance adds weight to Dynatrace’s existing growth and innovation story for...
NasdaqGS:GILD
NasdaqGS:GILDBiotechs

Is New HIV Switch Data Reframing the Investment Case for Gilead Sciences’ Lenacapavir Platform (GILD)?

In February 2026, Gilead Sciences presented Phase 3 ARTISTRY-1 and ARTISTRY-2 data showing its investigational single-tablet bictegravir/lenacapavir HIV regimen maintained virologic suppression and was generally well tolerated, proving noninferior to both complex multi-tablet regimens and guideline-recommended single-tablet therapy through Week 48. This potential new once-daily option could simplify treatment for people living with HIV who are currently on complex regimens, reinforcing...
NasdaqGS:HTZ
NasdaqGS:HTZTransportation

How Investors May Respond To Hertz Global Holdings (HTZ) Narrowing Losses And Pershing Square’s Comeback Framing

Hertz Global Holdings, Inc. reported past fourth-quarter 2025 sales of US$2,028 million versus US$2,040 million a year earlier, with its quarterly net loss narrowing to US$194 million from US$479 million; full-year 2025 sales were US$8.50 billion versus US$9.05 billion, while the annual net loss improved to US$747 million from US$2.86 billion. Pershing Square’s 2025 commentary framed Hertz as an emerging comeback story, highlighting a refreshed fleet, higher utilization, and the company’s...
NYSE:BHVN
NYSE:BHVNBiotechs

Why Biohaven (BHVN) Is Down 13.5% After Narrower Losses And A New Share Shelf Registration

In March 2026, Biohaven Ltd. reported fourth-quarter and full-year 2025 results showing its net loss narrowed to US$145.56 million for the quarter and US$738.82 million for the year, alongside reduced basic loss per share. On the same day, Biohaven also filed a US$134.78 million shelf registration for nearly 11.7 million common shares tied to an employee stock ownership plan, highlighting ongoing efforts to access capital and incentivize staff. We will now examine how Biohaven’s narrower...
NasdaqGS:TROW
NasdaqGS:TROWCapital Markets

Will T. Rowe Price’s New UK Retirement Lead (TROW) Subtly Reframe Its Long‑Term Strategy?

T. Rowe Price has appointed Richard Parkin as head of UK retirement, effective 9 March 2026, bringing over 35 years of pensions and retirement experience from roles at BNY Investments, Fidelity International, and key industry bodies. Parkin’s remit to shape the firm’s UK retirement strategy across retail and institutional channels highlights T. Rowe Price’s focus on expanding retirement solutions alongside its growing assets under management and earnings base. Next, we’ll examine how...
NasdaqGM:IESC
NasdaqGM:IESCConstruction

Does IES Holdings (IESC) Director Share Sale Recast the Story on Governance and Capital Allocation?

IES Holdings recently held its 2026 Annual Stockholders Meeting, where all director nominees were elected and Ernst & Young was ratified as auditor, while Director Todd Cleveland sold 2,500 shares, trimming his personal stake. Together with ongoing attention on the Gulf Island acquisition, these governance developments are sharpening investor focus on how IES allocates capital and manages oversight. Next, we’ll examine how the director’s share sale and refreshed governance framework shape...
SEHK:3393
SEHK:3393Electronic

Assessing Wasion Holdings (SEHK:3393) Valuation After Upgraded 2025 Profit Guidance

Wasion Holdings (SEHK:3393) issued new earnings guidance for 2025, projecting consolidated net profit of CN¥1,000 million to CN¥1,060 million, compared with about CN¥705.61 million in 2024, citing higher sales and tighter cost controls. See our latest analysis for Wasion Holdings. The new guidance comes after a powerful run in the shares, with a 90 day share price return of 78.42% and a 1 year total shareholder return that is more than triple the initial investment. This suggests that...
NasdaqGS:CHDN
NasdaqGS:CHDNHospitality

Does Churchill Downs (CHDN) Revenue-Earnings Split Recast Its Gaming-Led Growth Strategy?

Churchill Downs Incorporated has released its fourth-quarter and full-year 2025 results, showing higher revenue of US$665.9 million for the quarter and US$2.93 billion for the year, but lower net income of US$51.3 million and US$383 million respectively compared with the prior year. The company also opened Marshall Yards Racing & Gaming in Calvert City, Kentucky in February 2026, adding its eighth historical horse racing venue in the state and further tying gaming operations to purse funding...
NasdaqGS:ZVRA
NasdaqGS:ZVRAPharmaceuticals

Profit Swing, MIPLYFFA Uptake and New CFO Might Change The Case For Investing In Zevra Therapeutics (ZVRA)

Zevra Therapeutics, Inc. has reported its 2025 results, with full-year sales rising to US$106.47 million and net income reaching US$83.23 million, alongside fourth-quarter revenue of US$34.1 million and adjusted earnings of US$1.16 per share. Alongside these results, Zevra filed a US$22.86 million employee stock offering and named veteran finance executive Justin Renz as its new Chief Financial Officer, underscoring a focus on commercial scale-up and corporate development. We’ll now examine...
ASX:MFF
ASX:MFFCapital Markets

How Investors Are Reacting To MFF Capital Investments (ASX:MFF) Dividend, NTA Update and Director Buying

MFF Capital Investments has reported weekly net tangible assets per share of A$4.720 pre-tax and A$4.056 post-tax as at 6 March 2026, confirmed a 10 cent fully franked interim dividend, and scheduled an online-only shareholder webinar for 18 March 2026 with senior management presenting and taking questions. Director Chris Mackay’s recent on-market share purchases, combined with the upcoming webinar and maintained dividend, highlight stronger alignment between management and shareholders and...
NasdaqGS:MQ
NasdaqGS:MQDiversified Financial

Marqeta (MQ) Valuation Check After Q4 Results And 2026 Growth Outlook

Marqeta (MQ) is back in focus after its fourth quarter 2025 update, which paired higher reported sales and a sharply smaller net loss with fresh 2026 guidance on revenue and gross profit growth. See our latest analysis for Marqeta. Marqeta’s earnings update and 2026 guidance have arrived after a softer patch in the stock. The 7 day share price return of 4.88% contrasts with a 90 day share price return of negative 15.35% and a 3 year total shareholder return of negative 3.09%. This suggests...
OB:MPCC
OB:MPCCShipping

A Look At MPC Container Ships (OB:MPCC) Valuation After 2025 Results Guidance And Dividend Announcement

MPC Container Ships (OB:MPCC) is back in focus after releasing its fourth quarter and full year 2025 results, issuing 2026 revenue guidance and declaring a Q4 2025 dividend, moves that directly affect investor expectations. See our latest analysis for MPC Container Ships. The latest numbers and 2026 guidance seem to be feeding into strong momentum, with a 1 month share price return of 23.84% and year to date share price return of 31.62%. Meanwhile, the 1 year total shareholder return of...
HLSE:ORNBV
HLSE:ORNBVPharmaceuticals

A Look At Orion Oyj (HLSE:ORNBV) Valuation After BlackRock Crosses 5% Ownership Threshold

Institutional ownership change at Orion Oyj Orion Oyj (HLSE:ORNBV) came into focus after BlackRock, Inc. and its funds disclosed that their combined holdings had crossed the 5% ownership threshold in the company on 5 March 2026. See our latest analysis for Orion Oyj. At a share price of €68.55, Orion Oyj has seen a 12.56% 90 day share price return and a 30.41% 1 year total shareholder return, suggesting momentum has been generally positive even after a 7.18% 30 day share price pullback, with...
NYSE:OXY
NYSE:OXYOil and Gas

Occidental Petroleum (OXY) Valuation Check As Expanded Debt Buyback And Bondholder Support Draw Focus

Occidental Petroleum (OXY) is back in focus after it expanded the size of its cash tender offers to repurchase up to US$1.2b of outstanding notes and secured key bondholder consents. See our latest analysis for Occidental Petroleum. Occidental’s expanded tender offer and strong early bondholder participation come as the share price trades at US$55.02, with a 30 day share price return of 18.81% and year to date share price return of 29.83%. The 5 year total shareholder return of 100.16%...
NYSE:HTGC
NYSE:HTGCCapital Markets

Assessing Hercules Capital (HTGC) Valuation After Recent Share Price Weakness

Recent share performance and what it means for investors Hercules Capital (HTGC) has drawn investor attention after a recent pullback, with the stock showing negative returns over the past month and past 3 months, alongside a weaker move over the past year. At a last close of US$14.67, Hercules Capital sits below its recent levels. Returns of 76.11% over 3 years and 53.64% over 5 years provide a longer term contrast to its shorter term performance. See our latest analysis for Hercules...
NYSE:RMD
NYSE:RMDMedical Equipment

Assessing ResMed (RMD) Valuation As New Greenwood Distribution Hub Targets North American Growth

What ResMed’s new Greenwood hub could mean for the stock ResMed (RMD) is opening a new distribution center in Greenwood, Indiana, planned to start operations in 2027. The facility is intended to improve delivery coverage and speed for its sleep and respiratory care products across North America. See our latest analysis for ResMed. At a share price of US$252.93, ResMed has had a softer patch recently with a 30 day share price return of a 6.88% decline, even though its 1 year total shareholder...
TSX:CCO
TSX:CCOOil and Gas

Cameco (TSX:CCO) Is Down 8.2% After Securing US$2.6 Billion Indian Uranium Supply Deal

Cameco announced in early March 2026 that it had signed a long-term agreement to supply nearly 22 million pounds of uranium ore concentrate to India’s Department of Atomic Energy from 2027 to 2035, on market-linked terms, with an estimated contract value of about US$2.60 billion. This deal deepens Cameco’s role in India’s nuclear fuel supply as the country expands its reactor fleet toward a 100 GW nuclear capacity target by 2047. We’ll now examine how this nine-year Indian supply contract...
NasdaqGM:KYMR
NasdaqGM:KYMRBiotechs

A Look At Kymera Therapeutics (KYMR) Valuation After Equity Raise, Wider Losses And Leadership Change

Why Kymera’s latest update matters for shareholders Kymera Therapeutics (KYMR) has put several big items on the table at once, including a planned US$500 million at the market equity offering, wider quarterly and full year losses, and a new Chief Development Officer. These moves come as the company continues to invest in its protein degradation pipeline, and they raise practical questions for you around dilution, funding flexibility, and how leadership changes might influence the pace and...
NYSE:CPRI
NYSE:CPRILuxury

A Look At Capri Holdings (CPRI) Valuation After Tyler Reddien’s Appointment As CFO And COO

Leadership shift and upcoming conference draw attention to Capri Holdings stock The recent decision by Capri Holdings (CPRI) to appoint Tyler Reddien as both Chief Financial Officer and Chief Operating Officer, along with an upcoming appearance at Citi’s 2026 Global Consumer & Retail Conference, has brought fresh attention to the stock. See our latest analysis for Capri Holdings. Capri Holdings' share price has softened over the past year, with a 30 day share price return of a 9.22% decline...
SEHK:2007
SEHK:2007Real Estate

Country Garden Holdings (SEHK:2007) Valuation Check After February 2026 Contracted Sales Update

February sales announcement and what it tells you Country Garden Holdings (SEHK:2007) has released preliminary unaudited contracted sales for February 2026, reporting about RMB 2.23b in sales attributable to shareholders on roughly 0.29 million square meters of gross floor area. See our latest analysis for Country Garden Holdings. Investors have seen some short term share price strength recently, with a 1 month share price return of 10.71%. However, the 90 day share price return of 36.08% and...
NasdaqCM:BLTE
NasdaqCM:BLTEPharmaceuticals

The Bull Case For Belite Bio (BLTE) Could Change Following Steeply Wider 2025 Net Losses – Learn Why

Belite Bio, Inc reported fourth-quarter and full-year 2025 results, with net loss widening to US$25.32 million for the quarter and US$77.61 million for the year, compared with US$10.1 million and US$36.14 million respectively in the prior periods. The company is now absorbing materially higher per-share losses as it scales R&D and commercial infrastructure ahead of potential Tinlarebant approvals in rare retinal diseases. We’ll now examine how Belite Bio’s significantly wider 2025 net loss...
ASX:DVP
ASX:DVPMetals and Mining

Is Develop Global (ASX:DVP) Turning Modest Profit Gains Into a More Durable Earnings Model?

Develop Global Limited has released its half-year results for the period ended 31 December 2025, reporting sales of A$170.53 million versus A$113.02 million a year earlier, with net income rising to A$1.63 million from A$0.94 million and basic earnings per share from continuing operations increasing to A$0.005. While profit growth remains modest in absolute terms, the combination of higher revenue and improved diluted earnings per share underlines incremental operating progress across the...